New York, NY (PRWEB) July 07, 2014
As testosterone lawsuits (http://www.testosteronelawsuitclaims.com/) continue to mount in federal court, Bernstein Liebhard LLP notes the release of a new study by The Annals of Pharmacotherapy that examines the link between low testosterone therapies and heart attacks. The research, which was published online on July 2nd, did not find that older men who used prescription testosterone medications faced an increased risk of heart attack. However, the study authors did note that the research had a number of limitations, including the fact that the study only included men who received testosterone therapy via injection. As such, the authors called for future research, both observational studies and randomized clinical trials, to further examine potential adverse effects of testosterone therapy.*
“It should be noted that a number of previous studies have contradicted the findings of this research. In addition, many of the testosterone treatment lawsuits pending in U.S. courts were filed on behalf of men who allegedly suffered heart attacks and other cardiovascular problems due to testosterone creams and gels, which were not included in this research,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm offers free testosterone treatment lawsuit reviews to men who were allegedly harmed by medications included in this class.
Testosterone gels, patches and injections are approved to treat low testosterone (hypogonadism) in men who suffer from the condition due to an underlying medical issue. Medications in this class include:* *
According to a Drug Safety Communication issued by the U.S. Food & Drug Administration (FDA) in January, a number of studies have linked the use of prescription testosterone therapies to life-threatening cardiovascular events, including heart attacks and strokes. These included research that was published last November in the Journal of the American Medical System which reported an increased risk of heart attack, stroke and death among older men with pre-existing heart problems. A second study, which was published in PLOS One in January, reported that such treatments ware associated with a doubling of the heart attack risk among younger men with pre-existing heart problems, and in men over 65 regardless of their heart health.
In another alert published on June 20th, the FDA announced that it was requiring the manufacturers of all approved testosterone products to include a warning in the drug labeling about the potential for venous blood clots, including deep vein thrombosis and pulmonary embolism. While the agency noted that the labeling for the medications already includes information about venous blood clots that may occur due to the development of polycythemia, the modification was prompted by post-market reports of venous blood clots in testosterone patients unrelated to that condition.***
Court documents indicate that nearly 100 testosterone treatment lawsuits have been filed in the U.S. on behalf of men who allegedly suffered life-threatening cardiovascular problems, including heart attacks, strokes, heart failure, deep vein thrombosis, and pulmonary embolism, due to their use of low testosterone therapy. All federally-filed testosterone lawsuits have been consolidated in a multidistrict litigation that is now underway in U.S. District Court, Northern District of Illinois. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Men who allegedly suffered serious heart side effects due to their use of prescription testosterone therapies may be entitled to compensation from the manufacturers of these drugs. To learn more about filing a testosterone treatment lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*aop.sagepub.com/content/early/2014/06/20/1060028014539918.full, The Annals of Pharmacotherapy, July 2, 2014
**fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm402054.htm, FDA, June 20, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com